Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment.

Giulia GiacomucciSalvatore MazzeoSilvia BagnoliAssunta IngannatoDeborah LecceseValentina BertiSonia PadiglioniGiulia GaldoCamilla FerrariSandro SorbiValentina BessiBenedetta Nacmias

Published in: Journal of neurology (2022)

Plasma NfL levels might be a promising biomarker for neurodegeneration to discriminate cognitive decline due to AD from other conditions causing cognitive impairment in prodromal stages. Considering correlations with CSF p-tau and memory tests in SCD, NfL might be a useful peripheral biomarker also in preclinical phases of AD.

Keyphrases

cognitive decline
mild cognitive impairment
cognitive impairment
cerebrospinal fluid
stem cells
working memory
cell therapy
bone marrow
chemotherapy induced
deep brain stimulation